Urologie in der Praxis · Aug 6, 2026

Nutrition in prostate cancer during androgen deprivation therapy

By Bolte LA, Kaufmann A, Schläppi K et al.

ABSTRACT: Prostate cancer is the most common cancer in men. Because many patients have an excellent long-term prognosis, cardiometabolic comorbidities, accentuated by the side effects of androgen deprivation therapy (ADT), are becoming increasingly important. Unfavorable changes in body composition, blood glucose homeostasis, lipid profile, and blood pressure can be favorably influenced by targeted nutritional interventions. Nutrition also plays an important role in maintaining musculoskeletal health and thus preventing sarcopenia and osteoporosis. Initial randomized studies with small sample sizes in patients with prostate cancer demonstrate these effects. Based on the available evidence, a Mediterranean-style diet can be recommended, rich in healthy plant-based components, with moderate intake of processed carbohydrates and sufficient protein in combination with targeted resistance training. In cases of overweight/obesity, an energy-restricted and qualitatively optimized diet is indicated, and supportive glucagon-like peptide-1 (GLP-1)-based therapies may be helpful. Regarding effects on oncological outcomes, specific constituents such as lycopene, glucosinolates, and isoflavones are being investigated in preclinical models and epidemiological studies. However, robust data from randomized controlled trials with clinically relevant endpoints are largely lacking. Future studies with sufficiently large sample sizes should investigate how nutrition, other lifestyle measures, and new obesity medications influence the course of the disease, overall survival, and quality of life.

doi.org/10.1007/s41973-026-00341-8Open accessInterventions

AgingResearch.News